Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Myriam Weyl Ben Arush is active.

Publication


Featured researches published by Myriam Weyl Ben Arush.


Cancer | 1999

Nutritional status of children with solid tumors

Ronit Elhasid; Arie Laor; Sophie Lischinsky; Sergey Postovsky; Myriam Weyl Ben Arush

The purposes of the study were to evaluate prospectively the nutritional status of children with solid tumors who were receiving chemotherapy, to find the most sensitive parameter of protein energy malnutrition, and to determine whether the stage of disease and aggressiveness of chemotherapy have any influence on nutritional status.


Pediatric Hematology and Oncology | 2000

MALE GONADAL FUNCTION IN SURVIVORS OF CHILDHOOD HODGKIN AND NON-HODGKIN LYMPHOMA

Myriam Weyl Ben Arush; Ido Solt; Abraham Lightman; Shai Linn; A. Kuten

The aim of this study was to investigate the impact of therapy on long-term gonadal function of young people cured of childhood lymphomas and to assess whether a prepubertal state during the treatment protects the gonads from chemotherapy and/or radiotherapy late effects. Clinical evaluation, semen analysis, and endocrine status were studied in 20 survivors of childhood lymphomas. Five patients received Inverted Y radiotherapy, 2320 cGy (1550-4000); all 20 received chemotherapy as follows: MOPP/ABVD protocol, 9 patients; COMP protocol, 5 patients; MOPP protocol, 3 patients; other protocols, 3 patients. Semen analysis results were as follows: normal values, 4/20 patients; oligospermia, 8/20 patients; azoospermia, 8/20 patients; FSH above normal level, 10/20 patients; 4/5 who received Inverted Y irradiation were azoospermic and 1 was severely oligospermic. Treatment damage to the testis involves tubular germinal elements. Radiotherapy and chemotherapy combinations that included nitrogen mustard or cyclophosphamide were associated with high rates of oligospermia and azoospermia. MOPP/ABVD combination did not have a significant better outcome of sperm counts compared to MOPP alone. Age at chemotherapy did not correlate with the sperm count; hence a prepubertal state did not protect the gonad from the late effects of treatment.


European Journal of Nuclear Medicine and Molecular Imaging | 2007

The incremental value of 18F-FDG PET/CT in paediatric malignancies

Zvi Bar-Sever; Zohar Keidar; Ayelet Ben-Barak; Rachel Bar-Shalom; Sergey Postovsky; Luda Guralnik; Myriam Weyl Ben Arush; Ora Israel

Purpose18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) imaging has been used in the assessment of paediatric malignancies. PET/CT increases the diagnostic accuracy in adult cancer patients. The present study assesses the incremental value of FDG PET/CT in paediatric malignancies.MethodsA total of 118 18FDG PET/CT studies of 46 paediatric patients were reviewed retrospectively. PET and PET/CT results were classified as malignant, equivocal or benign, compared on a site- and study-based analysis, and also compared with the clinical outcome.ResultsThree hundred and twenty-four sites of increased FDG uptake were detected. Discordant PET and PET/CT interpretations were found in 97 sites (30%) in 27 studies (22%). PET yielded a statistically significant higher proportion of equivocal and a lower proportion of benign lesion and study results (p < 0.001) than PET/CT. With PET there were 153 benign (47%), 84 (26%) equivocal and 87 (27%) malignant sites, while PET/CT detected 226 benign (70%), 10 (3%) equivocal and 88 (27%) malignant lesions. PET/CT mainly improved the characterisation of uptake in brown fat (39%), bowel (17%), muscle (8%) and thymus (7%). The study-based analysis showed that 17 equivocal and seven positive PET studies (20%) were interpreted as benign on PET/CT, while three equivocal studies were interpreted as malignant. The study-based sensitivity and specificity of PET/CT were 92% and 78% respectively.ConclusionPET/CT significantly improved the characterisation of abnormal 18FDG foci in children with cancer, mainly by excluding the presence of active malignancy in sites of increased tracer activity.


Journal of Pediatric Hematology Oncology | 2006

Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities.

Myriam Weyl Ben Arush; Rachel Bar Shalom; Sergey Postovsky; Daniela Militianu; Motti Haimi; Irena Zaidman; Ora Israel

Alveolar rhabdomyosarcoma (ARS) accounts for 20% to 30% of childhood rhabdomyosarcoma and is known to have a worse prognosis than embryonal rhabdomyosarcoma. Metastatic disease is more frequent in patients with alveolar tumors and these children with metastatic disease fare poorly, with a 5-year survival between 20% and 30%. Therefore, ARS represents a significant diagnostic and therapeutic challenge that requires techniques to provide better assessment of the disease than provided by traditional means. F18 fluorodeoxyglucose-positron emission tomography (FDG-PET) depicts the increased metabolism in abnormal tissues, enabling accurate evaluation of suspicious regional and metastatic disease. The new combined PET/CT systems can further improve PET interpretation and affect patient management. The value of FDG in patients with soft tissue sarcomas has been demonstrated in several series, but none specifically in ARS. This report assesses the use of FDG-PET/CT in the detection of regional and metastatic nodes in 3 children diagnosed with ARS of the extremities. All the 3 patients we present had focally increased tracer uptake in nodal stations on a pretherapy PET performed at diagnosis. Tissue confirmation available in 2 patients was negative in 1 patient and positive for metastatic nodal spread in the other. Metastatic axillary disease was possibly also present in the third patient according to his later course of disease.


Pediatric Blood & Cancer | 2009

Optimal care for the child with cancer: A summary statement from the SIOP working committee on psychosocial issues in pediatric oncology†

John J. Spinetta; Momcilo Jankovic; Giuseppe Masera; Arthur R. Ablin; Ronald D. Barr; Myriam Weyl Ben Arush; Giulio J. D'Angio; Jeanette Van Dongen-Melman; Tim Eden; Claudia Epelman; Antonio Gentil Martins; Mark T. Greenberg; Helen Kosmidis; Daniel Oppenheim; Paul M. Zeltzer

Since its foundation in 1991, the SIOP Working Committee on Psychosocial Issues in Paediatric Oncology 1 has developed and published 12 sets of Guidelines for health‐care professionals treating children with cancer and their families. Those elements considered essential in the process of cure and care of children with cancer are summarized in this document as a formal statement, developed at the 2007 SIOP annual meeting in Mumbai. Elaboration of the concepts with detailed strategies for practice can be found in the referenced guidelines [1–12] and in a companion publication [13]. This article is a summary of what practitioners considered critical elements in the optimal care of the child with cancer, with the goal of stimulating a broader application of these elements throughout the SIOP membership. Pediatr Blood Cancer 2009;52:904–907.


Pediatric Blood & Cancer | 2005

Pediatric nasopharyngeal carcinoma: better prognosis and increased c-Kit expression as compared to adults.

Gil Bar-Sela; Myriam Weyl Ben Arush; Edmond Sabo; Abraham Kuten; Ira Minkov; Ofer Ben-Izhak

Nasopharyngeal carcinoma (NPC) in children is distinguishable from the adult form by its close association with Epstein‐Barr virus (EBV) infection, a higher rate of undifferentiated histology, and a greater incidence of advanced locoregional disease.


Journal of Pediatric Hematology Oncology | 2008

Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience.

Sergey Postovsky; Merav Barzilai; Itzhak Meller; Yehuda Kollander; Boris Futerman; Myriam Weyl Ben Arush

Despite comprehensive management of pediatric sarcomas, only 60% to 70% of children become long-term survivors. This study was undertaken to evaluate whether regular follow-up improves overall survival of children with recurrent sarcomas. The medical charts of 107 children diagnosed with soft tissue and bone sarcomas were reviewed, of whom 29 relapsed. They were divided into 2 groups according to the way of relapse diagnosis: due to complaints/physical examination (14) or on routine imaging studies (15). All were followed by regular physical examination and imaging studies (chest computed tomography, magnetic resonance imaging, and bone scan/positron emission tomography-computed tomography scan with fluorodeoxyglucose) at regular intervals. Analysis of the results showed that (1) regular imaging studies do not facilitate earlier recognition of relapse in children with sarcomas; (2) regular follow-up with imaging studies does not influence overall survival of children with sarcomas; (3) other diagnostic and treatment approaches are needed to improve the survival of children with recurrent sarcomas.


Pediatric Hematology and Oncology | 2001

DETECTION OF ISOLATED DISTANT METASTASIS IN SOFT TISSUE SARCOMA BY FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY: Case Report

Myriam Weyl Ben Arush; Ora Israel; Zohar Kedar; Ludmilla Goralnik; Lael-Anson Best; Nathanel Meushar; Ronit Elhasid; Sergey Postovsky

Fluorodeoxyglucose (FDG), labeled with F-18, is a glucoseanalog that accumulates in cells in proportion to the rate of glucose metabolism, and increased carbohydrate metabolism has been recognized as a feature of malignant cells versus normal cells. In addition, it permits the detection of metastases not discovered by bone scan. Although detection of the primary site of disease is usually accomplished well with conventional techniques, the performance of FDG positron emission tomography(PET)may be useful to determine metastases that are not clinically evident. The authors describe a case of early detection of distant metastasesby FDG-PET in a young patient diagnosed with rhabdomyosarcoma of the hand.


Pediatric Hematology and Oncology | 2000

Pediatric thyroid carcinoma : 22 years of experience at the Northern Israel Oncology Center (1973-1995)

Myriam Weyl Ben Arush; Moshe Stein; Monica Perez Nahum; Jamal Zidan; Abraham Kuten

Over the past 22 years, 16 children with thyroid carcinoma were referred to the Northern Israel Oncology Center. All patients had undergone surgical procedures, either total or subtotal thyroidectomy, and 7 patients had undergone cervical lymph node dissections. Postoperatively, 5 patients underwent thyroid ablation with radioactive 131I as first treatment. Two patients received postoperative external radiation therapy to a field encompassing the cervical region, superior mediastinum, and both supraclavicular grooves. After a median follow-up of 60 months (range, 5-169 months), all patients are alive with no evidence of recurrent disease. Two patients who had recurrences, one in the submaxillary lymph nodes and one in the lungs, were salvaged successfully with retreatment with 131I therapy. No severe acute or long-term side effects were exhibited. The long-term results of treatment of pediatric thyroid carcinoma are excellent, but there remains disagreement over the extent of surgical and postsurgical treatment required.


Pediatric Hematology and Oncology | 1995

Advanced Nasopharyngeal Carcinoma in the Young: The Northern Israel Oncology Center Experience, 1973–1991

Myriam Weyl Ben Arush; Moshe Stein; Edward Rosenblatt; R. Lavie; A. Kuten

Between 1973 and 1991, 10 patients with locally advanced [stages III and IV] nasopharyngeal carcinoma were treated at the Northern Israel Oncology Center. All patients were treated with wide-field irradiation to the primary tumor, including the base of skull, neck, and supraclavicular region. After 1984, 6 patients also received cisplatin/5FU-based chemotherapy prior to radiotherapy and 1 patient received it after radiotherapy. All the patients who received chemotherapy are alive with no evidence of disease, for a mean disease-free survival of 96 months (range, 77 to 108 months), and no serious therapy-related late side-effects have been noted, except in one patient. We conclude that adjuvant chemotherapy may be effective in improving outcome, but only randomized prospective studies can evaluate its exact role.

Collaboration


Dive into the Myriam Weyl Ben Arush's collaboration.

Top Co-Authors

Avatar

Sergey Postovsky

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Ronit Elhasid

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

John J. Spinetta

San Diego State University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Momcilo Jankovic

University of Milano-Bicocca

View shared research outputs
Top Co-Authors

Avatar

Tim O B Eden

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eugene Vlodavsky

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Antonio Gentil Martins

Instituto Português de Oncologia Francisco Gentil

View shared research outputs
Researchain Logo
Decentralizing Knowledge